|
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). |
|
|
Stock and Other Ownership Interests - Illumina; Merck |
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx |
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex |
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity |
Travel, Accommodations, Expenses - Genentech/Roche |
|
|
Honoraria - Bayer; Dendreon; Sanofi |
Consulting or Advisory Role - Agensys |
Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Acceleron Pharma; Agensys; Lilly; Rexahn Pharmaceuticals; TRACON Pharma |
|
|
Stock and Other Ownership Interests - Salus Discovery |
Research Funding - Agensys; Innocrin Pharma; Medivation |
Patents, Royalties, Other Intellectual Property - Salus Discovery |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; Progenics; progenics; Sanofi |
Expert Testimony - Celgene; sanofi |
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Roche |
|
|
Research Funding - Agensys (Inst); Aragon Pharmaceuticals (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Seagen (Inst); Tekmira (Inst); Teva (Inst) |
|
|
Honoraria - Astellas Pharma; Janssen Oncology |
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Research Funding - Sanofi (Inst) |
|
|
|
Stock and Other Ownership Interests - Seagen |
|
|
|
Stock and Other Ownership Interests - Amgen; Pfizer |
|
|
|
Stock and Other Ownership Interests - Amgen; Gilead Sciences; Vertex |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Astellas Pharma; Bayer |